PF-06821497 재발성/불응성 SCLC, 거세 저항성 전립선암 및 여포성 림프종의 치료
재발성/불응성 소세포 폐암(SCLC), 거세 저항성 전립선암(CRPC) 및 여포성 림프종(FL)을 가진 성인 환자의 치료에서 PF-06821497의 I상 용량 증량 및 확장 코호트 연구
The purpose of this study is to learn about the safety and effects of the study medicine (called Mevrometostat) for the possible treatment of Relapsed/ Refractory Small Cell Lung Cancer (SCLC), Castration Resistant Prostate Cancer (CRPC) and Follicular Lymphoma (FL). The study consists of 3 parts; Part 1 and 2 enrolled participants with SCLC, metastatic CRPC, and FL are closed for enrollment.
Part 3, which is open for enrollment is seeking men who:
- have Castration Resistant Prostate Cancer (CRPC) and
- have previously received treatment for CRPC and have progressed from the last treatment
All participants in Part 3 of this study will receive mevrometostat and/ or enzalutamide. Part 3 consists of 2 sub studies each has an assessment phase and a maintenance phase. The Part 3 DDI substudy consist of 2 cohorts, Cohort 1 (monotherapy cohort) and Cohort 2 (Combination cohort).
In the assessment phase:
- participants in the BE substudy will take 3 single doses of mevrometostat by mouth over 3 periods.
- participants in the DDI substudy Cohort 1 (monotherapy cohort) will take mevrometostat 2 times a day and/or itraconazole 1 time a day based on a present schedule.
- participants in the DDI substudy Cohort 2 (combination cohort) will take mevrometostat 2 times a day, enzalutamide 1 time a day, and/or itraconazole 1 time a day based on a present schedule.
After completion of the assessment phase, participants will enter the maintenance phase where they will receive mevrometostat 2 times a day and enzalutamide 1 time a day by mouth until their cancer is no longer responding.
The study will look at the experiences of participanrs receiving the study medicine. This will help see if the study medicine is safe and effective.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
상세 설명
This is an open label, multi center, Phase 1 dose escalation and dose expansion study of mevrometostat (PF-06821497) administered orally BID as a single agent or in combination with SOC to patients with CRPC, SCLC, and FL. The study consists of three parts (Part 1, Part 2, and Part 3) along with the Japan and China monotherapy cohorts. Part 1 and Part 2 are closed for enrollment. Part 1 tested monotherapy in 3 cohorts (Parts 1A, 1B, and 1C); Part 2 tested combination therapy in Parts 2A (dose escalation), 2B and 2C (does expansion).
Part 3 consists of the Bioequivalence (BE) and drug-drug interaction (DDI) substudies and are open for enrollment. The BE substudy will test between 2 mevrometostat formulation to confirm that they work in the body the same way. The DDI substudy will evaluate the effect of a strong CYP3A4 (an enzyme in your body that breaks down/ removes drugs) inhibitor on the PK of mevrometostat; a strong CYP3A4 inhibitor may slow down the breakdown/ removal of drugs in your body. The Sponsor may choose to delay or discontinue any cohorts or substudies.
연구 유형
연구 유형
등록 (추정된)
등록
단계
단계
- 1단계
연락처 및 위치
연구 연락처
연구 연락처
- 이름: Pfizer CT.gov Call Center
- 전화번호: 1-800-718-1021
- 이메일: ClinicalTrials.gov_Inquiries@pfizer.com
연구 장소
-
-
Kyǒnggi-do
-
Seongnam, Kyǒnggi-do, 대한민국, 13620
- 모병
- Seoul National University Bundang Hospital
-
-
Seoul-teukbyeolsi [seoul]
-
Seoul, Seoul-teukbyeolsi [seoul], 대한민국, 03080
- 모집하지 않고 적극적으로
- Seoul National University Hospital
-
Seoul, Seoul-teukbyeolsi [seoul], 대한민국, 07985
- 모집하지 않고 적극적으로
- Ewha Womans University Mokdong Hospital
-
Seoul, Seoul-teukbyeolsi [seoul], 대한민국, 03722
- 모집하지 않고 적극적으로
- Severance Hospital, Yonsei University Health System
-
-
Taejǒn-kwangyǒkshi
-
Daejeon, Taejǒn-kwangyǒkshi, 대한민국, 35015
- 모집하지 않고 적극적으로
- Chungnam national university hospital
-
-
-
-
-
Moscow, 러시아 제국, 117186
- 모집하지 않고 적극적으로
- LLC "Neyro-klinika"
-
Moscow, 러시아 제국, 125284
- 종료됨
- Moscow GBUZ "City clinical hospital n. a. S.P. Botkina" of Moscow health department
-
Moscow, 러시아 제국, 129301
- 종료됨
- SBHI of Moscow City Clinical Hospital
-
Omsk, 러시아 제국, 644013
- 종료됨
- Budgetary Healthcare Institution of Omsk region "Clinical Oncological Dispensary"
-
Saint Petersburg, 러시아 제국, 197341
- 종료됨
- Federal State Budgetary Institution National Medical Research Center n.a. V.A. Almazov
-
Saint Petersburg, 러시아 제국, 197758
- 종료됨
- Federal State Budgetary Institution National Medical Research Center for Oncology n.a. N.N.
-
Saint Petersburg, 러시아 제국, 198255
- 종료됨
- Saint Petersburg State Budgetary Healthcare Institution "City Clinical Oncological Dispensary"
-
Yaroslavl, 러시아 제국, 150054
- 종료됨
- State Budgetary Healthcare Institution of the Yaroslavl Region
-
-
Sankt-Peterburg
-
Pushkin, Sankt-Peterburg, 러시아 제국, 196603
- 모집하지 않고 적극적으로
- Private Medical Institution "Euromedservice"
-
-
-
-
Arizona
-
Tucson, Arizona, 미국, 85719
- 모집하지 않고 적극적으로
- Banner-University Medical Center Tucson
-
Tucson, Arizona, 미국, 85719
- 모집하지 않고 적극적으로
- The University of Arizona Cancer Center-North Campus
-
Tucson, Arizona, 미국, 85724
- 모집하지 않고 적극적으로
- The University of Arizona Cancer Center
-
Tucson, Arizona, 미국, 85741
- 종료됨
- Arizona Urology Specialists, PLLC
-
-
California
-
Anaheim, California, 미국, 92801
- 모집하지 않고 적극적으로
- Pacific Cancer Medical Center INC
-
Duarte, California, 미국, 91010
- 모집하지 않고 적극적으로
- City of Hope (City of Hope National Medical Center, City of Hope Medical Center)
-
Duarte, California, 미국, 91010
- 모집하지 않고 적극적으로
- City of Hope Investigational Drug Services (IDS)
-
-
Connecticut
-
Norwalk, Connecticut, 미국, 06856
- 모집하지 않고 적극적으로
- Norwalk Hospital
-
-
Kansas
-
Fairway, Kansas, 미국, 66205
- 모집하지 않고 적극적으로
- The University of Kansas Cancer Center, Investigational Drug Services
-
Fairway, Kansas, 미국, 66205
- 모집하지 않고 적극적으로
- The University of Kansas Clinical Research Center
-
Kansas City, Kansas, 미국, 66160
- 모집하지 않고 적극적으로
- The University of Kansas Hospital
-
Kansas City, Kansas, 미국, 66160
- 모집하지 않고 적극적으로
- The University of Kansas Medical Center Medical Office Building
-
Overland Park, Kansas, 미국, 66211
- 모집하지 않고 적극적으로
- The University of Kansas Cancer Center - Indian Creek Campus
-
Westwood, Kansas, 미국, 66205
- 모집하지 않고 적극적으로
- The University of Kansas Cancer Center
-
-
Kentucky
-
Louisville, Kentucky, 미국, 40202
- 모집하지 않고 적극적으로
- Norton Cancer Institute, Norton Healthcare Pavilion
-
Louisville, Kentucky, 미국, 40202
- 모집하지 않고 적극적으로
- Norton Hospital
-
Louisville, Kentucky, 미국, 40202
- 모집하지 않고 적극적으로
- Norton Cancer Institute - Downtown
-
-
Maryland
-
Rockville, Maryland, 미국, 20850
- 종료됨
- Maryland Oncology Hematology, P.A.
-
-
Massachusetts
-
Boston, Massachusetts, 미국, 02215
- 모집하지 않고 적극적으로
- Dana-Farber Cancer Institute
-
Boston, Massachusetts, 미국, 02115
- 모집하지 않고 적극적으로
- Brigham and Women's Hospital
-
Newton, Massachusetts, 미국, 02459
- 모집하지 않고 적극적으로
- Dana Farber Cancer Institute- Chestnut Hill
-
-
Nebraska
-
Omaha, Nebraska, 미국, 68130
- 모병
- Oncology Hematology West, PC dba Nebraska Cancer Specialists
-
-
New Jersey
-
Hackensack, New Jersey, 미국, 07601
- 모집하지 않고 적극적으로
- Hackensack University Medical Center
-
Hackensack, New Jersey, 미국, 07601
- 모집하지 않고 적극적으로
- John Theurer Cancer Center at Hackensack University Medical Center
-
-
Oklahoma
-
Oklahoma City, Oklahoma, 미국, 73104
- 모병
- OU Health University of Oklahoma Medical Center
-
Oklahoma City, Oklahoma, 미국, 73104
- 모병
- Stephenson Cancer Center (chemo location)
-
-
South Carolina
-
Myrtle Beach, South Carolina, 미국, 29572
- 모병
- Carolina Urologic Research Center
-
Myrtle Beach, South Carolina, 미국, 29572
- 모병
- Parkway Surgery Center
-
-
Tennessee
-
Nashville, Tennessee, 미국, 37203
- 모병
- Sarah Cannon Research Institute - Pharmacy
-
Nashville, Tennessee, 미국, 37203
- 모병
- SCRI Oncology Partners
-
-
Texas
-
Austin, Texas, 미국, 78705
- 종료됨
- Texas Oncology - Austin Midtown
-
Dallas, Texas, 미국, 75390
- 모집하지 않고 적극적으로
- UT Southwestern Medical Center
-
Dallas, Texas, 미국, 75390
- 모집하지 않고 적극적으로
- University of Texas Southwestern Medical Center - Simmons Cancer Center
-
Dallas, Texas, 미국, 75390
- 모집하지 않고 적극적으로
- UT Southwestern University Hospital - William P. Clements, Jr
-
Dallas, Texas, 미국, 75390
- 모집하지 않고 적극적으로
- UT Southwestern University Hospital - Zale Lipshy
-
Irving, Texas, 미국, 75063
- 종료됨
- US Oncology Investigational Product Center (IPC)
-
Irving, Texas, 미국, 75063
- 종료됨
- US Oncology Investigational Products Center
-
Irving, Texas, 미국, 75039
- 모병
- NEXT Dallas
-
San Antonio, Texas, 미국, 78229
- 모병
- NEXT Oncology
-
-
Virginia
-
Fairfax, Virginia, 미국, 22031
- 모집하지 않고 적극적으로
- Virginia Cancer Specialists, PC
-
-
Washington
-
Port Angeles, Washington, 미국, 98362
- 모집하지 않고 적극적으로
- Olympic Medical Center
-
Poulsbo, Washington, 미국, 98370
- 모집하지 않고 적극적으로
- Fred Hutchinson Cancer Center Alliance Peninsula
-
Seattle, Washington, 미국, 98195
- 모집하지 않고 적극적으로
- University of Washington Medical Center
-
Seattle, Washington, 미국, 98109
- 모집하지 않고 적극적으로
- Fred Hutchinson Cancer Center
-
-
-
-
-
Haskovo, 불가리아, 6300
- 종료됨
- Specialized Hospital for Active Treatment of Oncology - Haskovo
-
-
-
-
-
Barcelona, 스페인, 08035
- 모병
- Hospital Universitari Vall d'Hebron
-
Barcelona, 스페인, 08036
- 모병
- Hospital Clinic de Barcelona
-
Barcelona, 스페인, 08023
- 모병
- Hospital Quironsalud Barcelona
-
Madrid, 스페인, 28034
- 모병
- Hospital Universitario Ramon y Cajal
-
Madrid, 스페인, 28050
- 모병
- Hospital Universitario HM Sanchinarro
-
Madrid, 스페인, 28040
- 모병
- H.U. Fundación Jiménez Díaz
-
Madrid, 스페인, 28041
- 모병
- Hospital Universitario 12 De Octubre
-
Málaga, 스페인, 29010
- 모병
- Hospital Universitario Virgen de la Victoria
-
Valencia, 스페인, 46026
- 모집하지 않고 적극적으로
- Hospital Universitari i Politecnic La Fe
-
-
Barecelona
-
L'Hospitalet de Llobregat, Barecelona, 스페인, 08908
- 모집하지 않고 적극적으로
- Institut Català d´Oncología (ICO)-H. Durán i Reynals
-
-
Castellon
-
Castellon, Castellon, 스페인, 12002
- 모집하지 않고 적극적으로
- Consorcio Hospitalario Provincial de Castellon
-
-
Madrid
-
Pozuelo de Alarcón, Madrid, 스페인, 28223
- 모병
- Hospital Quironsalud Madrid
-
-
Madrid, Comunidad de
-
Madrid, Madrid, Comunidad de, 스페인, 28040
- 모병
- Hospital Clinico San Carlos
-
-
-
-
Chiba
-
Kashiwa, Chiba, 일본, 277-8577
- 모집하지 않고 적극적으로
- National Cancer Center Hospital East
-
-
-
-
Guangdong
-
Guangzhou, Guangdong, 중국, 510120
- 모집하지 않고 적극적으로
- The First Affiliated Hospital of Guangzhou Medical University
-
-
Hunan
-
Changsha, Hunan, 중국, 410013
- 모집하지 않고 적극적으로
- Hunan Cancer Hospital
-
-
Jiangsu
-
Nanjing, Jiangsu, 중국, 210009
- 모집하지 않고 적극적으로
- Zhongda Hospital Southeast University
-
Nanjing, Jiangsu, 중국, 210008
- 모집하지 않고 적극적으로
- Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School
-
-
Sichuan
-
Chengdu, Sichuan, 중국, 610041
- 모병
- West China Hospital, Sichuan University
-
-
Zhejiang
-
Wenzhou, Zhejiang, 중국, 325000
- 모집하지 않고 적극적으로
- The First Affiliated Hospital of Wenzhou Medical University
-
-
-
-
-
Bydgoszcz, 폴란드, 85-048
- 아직 모집하지 않음
- In-Vivo Sp. z o.o. In-vivo Bydgoszcz
-
Koszalin, 폴란드, 75-581
- 모집하지 않고 적극적으로
- Szpital Wojewódzki im. Mikołaja Kopernika w Koszalinie
-
Krakow, 폴란드, 30-348
- 모병
- Centrum Badań Klinicznych Jagiellońskie Centrum Innowacji sp. z o.o.
-
Rzeszów, 폴란드, 35-326
- 모집하지 않고 적극적으로
- Centrum Medyczne MEDYK
-
Warsaw, 폴란드, 02-781
- 모집하지 않고 적극적으로
- Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Part 1 and Part 2 (Closed for enrollment).
Part 3 Key Inclusion Criteria:
- Histological or cytological diagnosis of castration resistant prostate cancer.
- Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0-2 with expected life expectancy of at least 6 months.
- Adequate bone marrow, renal, and liver function
Part 3 Key Exclusion Criteria:
- Prior irradiation to >25% of the bone marrow.
- QTcF interval >480 msec at screening.
- Hypertension that cannot be controlled by medications (>150/90 mmHg despite optimal medical therapy).
- Known or suspected hypersensitivity to PF 06821497 or any components or enzalutamide (CRPC)
- Active inflammatory gastrointestinal disease, chronic diarrhea, known diverticular disease or previous gastric resection or lap band surgery.
- Current use or anticipated need for food or drugs that are known strong and moderate CYP3A4/5 inducers or inhibitors
- Prior enzalutamide within the last 4 weeks
- DDI SUBSTUDY:
- history of CHF or evidence of ventricular dysfunction
- fructose intolerance
- coadministration of CYP3A4 substrates
- Any history of prior malignancies, except for carcinoma in situ or non-melanoma skin cancer, prior non-hematologic malignancies >= 3 years before randomization with no subsequent recurrence or progression, Stage 0 or 1 non-hematologic cancer < 3 years before randomization that has a remote probability of recurrence or progression.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 순차적 할당
- 마스킹: 없음(오픈 라벨)
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: Dose Escalation (Part 1A)
Participants with SCLC, CRPC and FL will receive mevrometostat at escalating dose levels |
Oral continuous
다른 이름들:
|
|
실험적: Dose Escalation (Part 1B)
Participants with FL will receive mevrometostat at escalating dose levels |
Oral continuous
다른 이름들:
|
|
실험적: Dose Escalation (Part 1C)
Participants with mCRPC will receive mevrometostat at escalating dose levels. |
Oral continuous
다른 이름들:
|
|
실험적: Dose Escalation (Part 2A)
Participants with mCRPC and SCLC will receive mevrometostat at escalating dose levels in combination with SOC. |
Oral continuous
다른 이름들:
Oral continuous
다른 이름들:
|
|
실험적: Dose Expansion (Part 2B)
Participants with CRPC will receive mevrometostat in combination with SOC or SOC alone. |
Oral continuous
다른 이름들:
Oral continuous
다른 이름들:
|
|
실험적: Japan Cohort
Participants with CRPC will receive mevrometostat at one or two doses |
Oral continuous
다른 이름들:
|
|
실험적: China cohort
Participants will receive mevrometostat at one or two doses |
Oral continuous
다른 이름들:
|
|
실험적: Dose Expansion (Part 2C)
Participants with mCRPC will receive mevrometostat at a different dose/dosing regimen than that of Part 2B in combination with SOC |
Oral continuous
다른 이름들:
Oral continuous
다른 이름들:
|
|
실험적: BE Substudy
In the assessment phase, each enrolled participant will receive single doses of the 2 different mevrometostat formulations in 3 periods with alternating dosing and washout between each dose. In the maintenance phase, each participant will receive mevrometostat 2 times a day and enzalutamide 1 time a day. |
Oral continuous
다른 이름들:
Oral continuous
다른 이름들:
|
|
실험적: DDI Substudy
The DDI substudy assessment phase will consist of 2 Cohorts, Cohort 1 (monotherapy cohort) and Cohort 2 (combination cohort). In the Cohort 1 assessment phase, each enrolled participant will receive a combination of mevrometostat and itraconazole based on preset schedule. In the Cohort 2 assessment phase, each enrolled participant will receive a combination of mevrometostat, enzalutamide, and itraconazole based on preset schedule. In the maintenance phase, each participant will receive mevrometostat 2 times a day and enzalutamide 1 time a day. |
Oral continuous
다른 이름들:
Oral continuous
다른 이름들:
Oral solution
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Percentage of patients with dose limiting toxicities (DLTs) to determine the maximum tolerated dose (MTD)
기간: Baseline up to 90 days
|
First cycle DLTs will be utilized to determine the MTD |
Baseline up to 90 days
|
|
Overall safety profile including adverse events
기간: Baseline up to approximately 2 years
|
Adverse Events will be graded by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE version [4.03]) |
Baseline up to approximately 2 years
|
|
Preliminary efficacy determination as evaluated by disease specific response criteria
기간: Through study completion, approximately 2 years past last patient first visit.
|
Objective response using Response Evaluation Criteria in Lymphoma (RECIL) for lymphoma, Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 for solid tumors including Small Cell Lung Cancer (SCLC) and Prostate Cancer Working Group 3 (PCWG3) for Castration Resistant Prostate Cancer (CRPC). Progression-free survival in Part 2B in patients with CRPC. |
Through study completion, approximately 2 years past last patient first visit.
|
|
Overall safety profile including laboratory abnormalities
기간: Baseline up to approximately 2 years
|
Laboratory abnormalities as characterized by type, frequency, severity (as graded by NCI CTCAE version [4.03]), and timing. |
Baseline up to approximately 2 years
|
|
Overall safety profile including vital signs
기간: Baseline up to approximately 2 years
|
Vital sign changes from baseline including blood pressure, heart rate, ECG changes. |
Baseline up to approximately 2 years
|
|
Evaluate time to event mevrometostat and enzalutamide vs enzalutamide alone including radiographic prgression free survival
기간: Baseline until disease progression or death or through study completion (approx 2 years)
|
PCWG3 |
Baseline until disease progression or death or through study completion (approx 2 years)
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Evaluate time to event anti-tumor activity of mevrometostat including progression-free survival (PFS), PSA50, Duration of Response (DoR), Time to first skeletal related event and Time to symptomatic skeletal related event, depending on tumor type.
기간: Baseline and every 21 days through time of confirmed disease progression, unacceptable toxicity, or through study completion, approximately 2 years.
|
Time to event endpoints based on Response Evaluation Criteria in Lymphoma (RECIL) for lymphoma, Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 for solid tumors including Small Cell Lung Cancer (SCLC) and Prostate Cancer Working Group 3 (PCWG3) for Castration Resistant Prostate Cancer (CRPC) |
Baseline and every 21 days through time of confirmed disease progression, unacceptable toxicity, or through study completion, approximately 2 years.
|
|
Evaluate overall survival
기간: Baseline up to approximately 2 years
|
Median time to death proportion of patients alive at 6 months, 1 year, and 2 years. |
Baseline up to approximately 2 years
|
|
Pharmacokinetic Parameters: Maximum Observed Plasma Concentration (Cmax)
기간: At specific timepoints from Cycle 1 day 1 to End of Treatment visit
|
Single dose and multiple dose PK will be calculated as data permits |
At specific timepoints from Cycle 1 day 1 to End of Treatment visit
|
|
Pharmacokinetic Parameters: Time to Reach Maximum Observed Plasma Concentration (Tmax)
기간: At specific timepoints from Cycle 1 day 1 to End of Treatment visit
|
Single dose and multiple dose PK will be calculated as data permits |
At specific timepoints from Cycle 1 day 1 to End of Treatment visit
|
|
Pharmacokinetic Parameters: Area Under the Curve (AUC)
기간: At specific timepoints from Cycle 1 day 1 to End of Treatment visit
|
Single dose and multiple dose PK will be calculated as data permits |
At specific timepoints from Cycle 1 day 1 to End of Treatment visit
|
|
Pharmacokinetic Parameters: Apparent Oral Clearance (CL/F)
기간: At specific timepoints from Cycle 1 day 1 to End of Treatment visit
|
Single dose and multiple dose PK will be calculated as data permits |
At specific timepoints from Cycle 1 day 1 to End of Treatment visit
|
|
Pharmacokinetic Parameters: Apparent Volume of Distribution (Vz/F)
기간: At specific timepoints from Cycle 1 day 1 to End of Treatment visit
|
Single dose and multiple dose PK will be calculated as data permits |
At specific timepoints from Cycle 1 day 1 to End of Treatment visit
|
|
Pharmacokinetic Parameters: Plasma Decay Half-Life (t1/2)
기간: At specific timepoints from Cycle 1 day 1 to End of Treatment visit
|
Singe dose and multiple dose PK will be calculated as data permits |
At specific timepoints from Cycle 1 day 1 to End of Treatment visit
|
|
Evaluate the impact of mevrometostat on patient reported outcomes.
기간: At specific time-points from Cycle 1 Day 1 to End of Treatment visit.
|
Quality of Life and Time to Functional Status Deterioration as assessed by FACT-P. |
At specific time-points from Cycle 1 Day 1 to End of Treatment visit.
|
|
Impact of mevrometostat in combination with enzalutamide, enzalutamide alone and mevrometostat alone on symptoms and symptomatic toxicity
기간: At specific time points from Cycle1 Day 1 to end of treatment
|
Questionnaire customized from PRO-CTCAE. |
At specific time points from Cycle1 Day 1 to end of treatment
|
공동 작업자 및 조사자
수사관
수사관
- 연구 책임자: Pfizer CT.gov Call Center, Pfizer
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
키워드
추가 관련 MeSH 약관
기타 연구 ID 번호
기타 연구 ID 번호
- C2321001
- 2023-509179-18-00 (레지스트리 식별자: CTIS (EU))
- EZH2 (기타 식별자: Alias Study Number)
- 2023 (미국 NIH 보조금/계약)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .